Therapy-induced tumor immunosurveillance involves IFN-producing killer dendritic cells

Evelyn Ullrich; Mathieu Bonmort; Grégoire Mignot; Nathalie Chaput; Julien Taieb; Cédric Ménard; Sophie Viaud; Thomas Tursz; Guido Kroemer; Laurence Zitvogel

doi:10.1158/0008-5472.CAN-06-3766

Therapy-induced tumor immunosurveillance involves IFN-producing killer dendritic cells

Evelyn Ullrich, Mathieu Bonmort, Grégoire Mignot, Nathalie Chaput, Julien Taieb, Cédric Ménard, Sophie Viaud, Thomas Tursz, Guido Kroemer, Laurence Zitvogel

Résultats de recherche: Contribution à un journal › Article 'review' › Revue par des pairs

34 Citations (Scopus)

Résumé

A unique class of IFN-producing killer dendritic cells (IKDC) resembling natural killer cells has been defined that can recognize and lyse tumor cells through a tumor necrosis factor-related apoptosis-inducing ligand-dependent mechanism. IKDC may mediate the host-dependent antitumor activity of Gleevec/STI571 and other therapeutics that can inhibit the c-kit tyrosine kinase. IKDC represent an important new component of the innate immune system responding to cancer.

langue originale	Anglais
Pages (de - à)	851-853
Nombre de pages	3
journal	Cancer Research
Volume	67
Numéro de publication	3
Les DOIs	https://doi.org/10.1158/0008-5472.CAN-06-3766
état	Publié - 1 févr. 2007

Accès au document

10.1158/0008-5472.CAN-06-3766

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{e3d671ee5ccb4e058c73690607a62d53,

title = "Therapy-induced tumor immunosurveillance involves IFN-producing killer dendritic cells",

abstract = "A unique class of IFN-producing killer dendritic cells (IKDC) resembling natural killer cells has been defined that can recognize and lyse tumor cells through a tumor necrosis factor-related apoptosis-inducing ligand-dependent mechanism. IKDC may mediate the host-dependent antitumor activity of Gleevec/STI571 and other therapeutics that can inhibit the c-kit tyrosine kinase. IKDC represent an important new component of the innate immune system responding to cancer.",

author = "Evelyn Ullrich and Mathieu Bonmort and Gr{\'e}goire Mignot and Nathalie Chaput and Julien Taieb and C{\'e}dric M{\'e}nard and Sophie Viaud and Thomas Tursz and Guido Kroemer and Laurence Zitvogel",

year = "2007",

month = feb,

day = "1",

doi = "10.1158/0008-5472.CAN-06-3766",

language = "English",

volume = "67",

pages = "851--853",

journal = "Cancer Research",

issn = "0008-5472",

number = "3",

}

TY - JOUR

T1 - Therapy-induced tumor immunosurveillance involves IFN-producing killer dendritic cells

AU - Ullrich, Evelyn

AU - Bonmort, Mathieu

AU - Mignot, Grégoire

AU - Chaput, Nathalie

AU - Taieb, Julien

AU - Ménard, Cédric

AU - Viaud, Sophie

AU - Tursz, Thomas

AU - Kroemer, Guido

AU - Zitvogel, Laurence

PY - 2007/2/1

Y1 - 2007/2/1

N2 - A unique class of IFN-producing killer dendritic cells (IKDC) resembling natural killer cells has been defined that can recognize and lyse tumor cells through a tumor necrosis factor-related apoptosis-inducing ligand-dependent mechanism. IKDC may mediate the host-dependent antitumor activity of Gleevec/STI571 and other therapeutics that can inhibit the c-kit tyrosine kinase. IKDC represent an important new component of the innate immune system responding to cancer.

AB - A unique class of IFN-producing killer dendritic cells (IKDC) resembling natural killer cells has been defined that can recognize and lyse tumor cells through a tumor necrosis factor-related apoptosis-inducing ligand-dependent mechanism. IKDC may mediate the host-dependent antitumor activity of Gleevec/STI571 and other therapeutics that can inhibit the c-kit tyrosine kinase. IKDC represent an important new component of the innate immune system responding to cancer.

UR - http://www.scopus.com/inward/record.url?scp=33847016148&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-06-3766

DO - 10.1158/0008-5472.CAN-06-3766

M3 - Review article

C2 - 17283111

AN - SCOPUS:33847016148

SN - 0008-5472

VL - 67

SP - 851

EP - 853

JO - Cancer Research

JF - Cancer Research

IS - 3

ER -